<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03223103</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 17-0566</org_study_id>
    <secondary_id>16-089</secondary_id>
    <nct_id>NCT03223103</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma</brief_title>
  <official_title>Phase I Study of Tumor Treatment Fields and a Personalized Mutation-derived Tumor Vaccine in Patients With Newly Diagnosed Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adilia Hormigo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NovoCure Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use precision medicine in the form of a vaccine, a&#xD;
      mutation-derived tumor antigen vaccine (MTA-based vaccine) in combination with standard care&#xD;
      treatment of glioblastoma (GBM) and Tumor Treating Fields (TTFields).&#xD;
&#xD;
      The study is designed to determine whether this treatment combination is well tolerated and&#xD;
      safe.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-arm, single institution phase 1a / 1b study to test the safety,&#xD;
      tolerability, and immunogenicity of MTA-based personalized vaccine in patients with newly&#xD;
      diagnosed GBM along with the use of continual TTFields. MTA-based personalized vaccine is&#xD;
      prepared in the laboratory with several peptides based on each patient's own tumor sequence.&#xD;
&#xD;
      The vaccine is given after the radiation and chemotherapy portion of the treatment, in the&#xD;
      maintenance phase of temozolomide in conjunction with the TTFields.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Actual">July 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities (DLT)</measure>
    <time_frame>42 weeks</time_frame>
    <description>Feasibility administration of one vaccine; toxicity will be measured by severity of Adverse events with toxicity grading defined by Cancer Therapy Evaluation Program's (CTEP) v4.0 of National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity grading using CTCAE scale</measure>
    <time_frame>1 year</time_frame>
    <description>Safety will be measured by number of Adverse events with toxicity grading defined by Cancer Therapy Evaluation Program's (CTEP) v4.0 of National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent Progression Free Survival (PFS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>2 years</time_frame>
    <description>Overall response as measured by RANO Response Criteria: Complete response, Partial response, Stable Disease, and Progressive Disease</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Mutation-derived tumor vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MTA-based Personalized Vaccine (peptides + Poly-ICLC with Tumor Treating Fields</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Poly-ICLC</intervention_name>
    <description>Poly-ICLC 100mcg per peptide per dose</description>
    <arm_group_label>Mutation-derived tumor vaccine</arm_group_label>
    <other_name>Hiltonol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tumor Treating Fields</intervention_name>
    <description>an FDA approved treatment for patients with recurrent GBM and newly diagnosed GBM</description>
    <arm_group_label>Mutation-derived tumor vaccine</arm_group_label>
    <other_name>Optune®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peptides</intervention_name>
    <description>synthetic long peptides (SLP) as vaccine substrate</description>
    <arm_group_label>Mutation-derived tumor vaccine</arm_group_label>
    <other_name>Personalized peptides</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Confirmation of GBM (WHO grade IV).&#xD;
&#xD;
          -  Maximal debulking surgery and undergo radiotherapy concomitant with Temozolomide&#xD;
             (45-70Gy)&#xD;
&#xD;
          -  Stable disease after treatment of radiation with chemotherapy&#xD;
&#xD;
          -  Life expectancy &gt; 16 weeks.&#xD;
&#xD;
          -  Performance status of 0-2 (Eastern Cooperative Oncology Group).&#xD;
&#xD;
          -  First vaccine treatment start date at least 4 weeks out but not more than 8 weeks from&#xD;
             the last dose of concomitant Temozolomide or radiotherapy.&#xD;
&#xD;
          -  Must have tumor tissue sufficient sequencing.&#xD;
&#xD;
          -  Have adequate bone marrow function&#xD;
&#xD;
          -  Require Dexamethasone ≤ 4mg daily on a stable dose&#xD;
&#xD;
          -  Acceptable hematologic, hepatic, and renal function and these tests must be performed&#xD;
             within 14 days prior to study&#xD;
&#xD;
          -  The participant must be deemed competent to give informed consent.&#xD;
&#xD;
          -  The participant must agree to use two effective forms of contraception beginning at&#xD;
             least four (4) weeks prior to study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Progression of disease at time of screening.&#xD;
&#xD;
          -  Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, other&#xD;
             implanted electronic devices in the brain, or documented clinically significant&#xD;
             arrhythmias.&#xD;
&#xD;
          -  Infra-tentorial tumor or multifocal disease.&#xD;
&#xD;
          -  History of hypersensitivity reaction to Temozolomide.&#xD;
&#xD;
          -  Receiving any other investigational agents.&#xD;
&#xD;
          -  Prior history of unrelated neoplastic disease, and having received systemic therapy&#xD;
             for the secondary malignancy within the twelve (12) month period preceding the&#xD;
             screening evaluation.&#xD;
&#xD;
          -  (HIV/AIDS), Chronic hepatitis B or hepatitis C.&#xD;
&#xD;
          -  History of, or is reasonably suspected to meet criteria for the diagnosis of a known&#xD;
             congenital or acquired disorder causing systemic immunosuppression.&#xD;
&#xD;
          -  History of, or is reasonably suspected to meet criteria for the diagnosis of a&#xD;
             systemic auto-immune/inflammatory disease or other autoimmune disorder with the&#xD;
             exception of: Vitiligo&#xD;
&#xD;
          -  Positive pregnancy test [45 CFR 46.203(b)].&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adilia Hormigo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2017</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Adilia Hormigo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Brain cancer</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Personalized vaccine</keyword>
  <keyword>Poly-ICLC</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Cancer</keyword>
  <keyword>NovoTTF-200A</keyword>
  <keyword>Optune</keyword>
  <keyword>GBM</keyword>
  <keyword>immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poly ICLC</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

